![]() The Koide group continues to push the Monobody technology forward and develop novel applications.Īffinity Clamps are synthetic proteins designed for recognizing short peptide motifs with high specificity and high affinity. Since our original publication, the FN3 scaffold has become the most widely adopted system for generating non-antibody binding proteins. In contrast, most antibodies and antibody fragments must be produced under oxidizing conditions, due to their dependence on disulfide bonds, and their two chains must be properly assembled. This is because of unique characteristics of the underlying FN3 scaffold: small (~90 residues), stable, easy to produce, and its lack of disulfide bonds that makes it possible to produce functional monobodies in the reducing environment of the cytoplasm. Most monobodies bind a functional site of their targets and thus the monobody technology offers a powerful means to rapidly producing highly potent inhibitors.Ī major advantage of monobodies over conventional antibodies is that monobodies can readily be used as genetically encoded intracellular inhibitors, that is you can express a monobody inhibitor in a cell of choice by simply transfecting the cell with a monobody expression vector. We have successfully generated a large number of monobodies that have high affinity and high specificity to their respective targets. Monobodies are produced from combinatorial libraries in which portions of the FN3 scaffold are diversified using highly tailored mixtures of amino acids by utilizing phage display and yeast surface display techniques. In 1998, we published the first paper demonstrating the monobody concept using the tenth FN3 domain of human fibronectin. Monobodies are simple and robust alternative to antibodies in creating target-binding proteins. Monobodies are synthetic binding proteins that are constructed using a fibronectin type III domain (FN3) as a molecular scaffold. We have pioneered a number of transformative technologies in protein design and engineering including the monobody and affinity clamp systems. The Koide group makes substantial investment of effort and resources to developing new technologies. New technologies often catalyze major progress in science and engineering. ![]() Recombinant DNA technologies – mutagenesis, protein expression.Structural Biology – x-ray crystallography, nuclear magnetic resonance spectroscopy.Biophysics – protein interactions protein stability protein structure.Directed evolution – phage display yeast surface display.Our research is highly interdisciplinary, and we develop and utilize many technologies in: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |